Long non-coding RNA CASC2 in human cancer

Palmieri, Giuseppe; Paliogiannis, Panagiotis; Sini, Maria Cristina; Manca, Antonella; Palomba, Grazia; Doneddu, Valentina; Tanda, Francesco; Pascale, Maria Rosa; Cossu, Antonio

doi:10.1016/j.critrevonc.2017.01.003

Cited by 58 publications

(50 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CASC2 has been shown to be low expressed in several human tumors and played a tumor-suppressor role in tumorigenesis and development. 23 In this work, we observed a marked downregulation of CASC2 expression in human HCC tissues, which was consistent with its expression profile in other tumors. We hypothesized that CASC2 with onco-suppressor effects played a certain function in HCC and this conclusion was further evidenced in terms of the observation of the lower expression of CASC2 in HCC cell lines.…”

Section: Discussionsupporting

confidence: 88%

LncRNA CASC2 inhibited the viability and induced the apoptosis of hepatocellular carcinoma cells through regulating miR‐24‐3p

Fan

Zeng

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

Cancer susceptibility candidate 2 (CASC2), a recently discovered long non-coding RNA (lncRNA), was confirmed to play numerous roles in several human cancers. However, the involvement and concrete mechanism of CASC2 in hepatocellular carcinoma (HCC) still need to be further elucidated. The relative expressions of CASC2 and miR-24-3p in HCC tissue and cell lines were determined by quantitative real-time PCR (qRT-PCR). The effects of CASC2 and miR-24-3p on HCC cells were further assessed via cell viability and apoptosis. In vivo tumorigenesis assay was performed to verify the inhibition effect of CASC2 on the tumor growth and further clarify the important role of miR-24-3p in this mechanism. Compared with the paired normal tissues, the relative expression of CASC2 significantly reduced in the HCC tissues, while miR-24-3p as determined by qRT-PCR obviously increased in the HCC tissues. This observation was also found in HCC cell lines. Meanwhile, the expression of CASC2 was negatively related to miR-24-3p expression in the HCC tissues (r = -0.804, P < 0.001). CASC2 could negatively regulate the expression of miR-24-3p in vitro. Moreover, CASC2 overexpression resulted in the growth inhibitory and apoptosis-inducing effects on HCC cells, but the up-regulation of miR-24-3p greatly eliminated the CASC2-induced effects. The tumorigenesis of HCC cells was restrained significantly by CASC2 overexpression as shown by decreased tumor volume and growth rate. However, miR-24-3p up-regulation rescued the inhibition of CASC2 on the tumor growth in tumor-bearing mice. LncRNA CASC2 inhibited the viability and induced the apoptosis of HCC cells through regulating miR-24-3p.

show abstract

Section: Discussionsupporting

confidence: 88%

LncRNA CASC2 inhibited the viability and induced the apoptosis of hepatocellular carcinoma cells through regulating miR‐24‐3p

Fan

Zeng

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…Long non‐coding RNAs (lncRNAs) are non‐protein‐coding RNA segments with lengths greater than 200 nucleotides that have been shown to play crucial roles in the regulation of a variety of cancers (Palmieri et al, ). They do so specifically by regulating gene expression at the transcriptional or posttranscriptional level to alter activities such as cell cycle progression and proliferation.…”

Section: Introductionmentioning

confidence: 99%

Long noncoding RNA CASC2 regulates hepatocellular carcinoma cell oncogenesis through miR‐362‐5p/Nf‐κB axis

Zhao

Zhang

2018

Journal Cellular Physiology

View full text Add to dashboard Cite

The long non-coding RNA segment cancer susceptibility candidate 2 (CASC2) has been shown to suppress tumor growth in a variety of cancers, including hepatocellular carcinoma (HCC). However, the mechanism by which CASC2 exerts control over HCC has yet to be established. In the present study, we first demonstrated that CASC2 is downregulated in human HCC tissues and HCC cell lines as compared to adjacent non-tumor tissues (NTTs) and a liver cell line, respectively. After finding that CASC2 knockdown significantly promotes HCC cells migration and invasion as well as that CASC2 overexpression inhibits cell migration and invasion, we identified the microRNA miR-362-5p as an endogenous target of CASC2. Through the use of wild type and mutant CASC2 binding sites inserted into psiCHECK-2 luciferase reporter plasmids, as well as qRT-PCR, we determined that CASC2 overexpression reduces miR-362-5p expression levels, while inhibiting CASC2 activity increases miR-362-5p expression. Past research has shown that miR-362-5p stimulates the NF-κB pathway, which has been implicated in the survival and proliferation of a variety of cancer cells. We therefore investigated the effects of CASC2 expression on NF-κB pathway activity. Ultimately, we determined that CASC2 regulates HCC cell activity by targeting miR-362-5p and thus inhibiting the NF-κB pathway. The present study not only identifies CASC2 as an important HCC cell regulator, but also suggests its mechanism of action. It therefore provides the basis for designing strategies to target CASC2 activity and thereby inhibit HCC growth and progression.

show abstract

“…Evidence suggested that the expression levels of CASC2b and CASC2c mRNA were similar in normal and neoplastic endometrial tissues; whereas, CASC2a was identified to be downregulated in neoplastic samples compared with the normal counterparts (5). Since then, further studies in other types of neoplasia have been conducted, and the mechanisms and the interactions of CASC2 in cancer have been better elucidated (35); in addition, CASC2 has become synonymous with CASC2a. Aberrant expression of CASC2 was detected in renal cell carcinoma (12), osteosarcoma (36), pancreatic cancer (13), endometrial cancer (6), hepatocellular carcinoma (37), glioma (10,38,39), non-small cell lung cancer (8) and gastric cancer (11).…”

Section: Discussionmentioning

confidence: 99%

Long non‑coding RNA CASC2 inhibits progression and predicts favorable prognosis in epithelial ovarian cancer

2018

View full text Add to dashboard Cite

show abstract

Long non-coding RNA CASC2 in human cancer

Cited by 58 publications

References 61 publications

LncRNA CASC2 inhibited the viability and induced the apoptosis of hepatocellular carcinoma cells through regulating miR‐24‐3p

LncRNA CASC2 inhibited the viability and induced the apoptosis of hepatocellular carcinoma cells through regulating miR‐24‐3p

Long noncoding RNA CASC2 regulates hepatocellular carcinoma cell oncogenesis through miR‐362‐5p/Nf‐κB axis

Long non‑coding RNA CASC2 inhibits progression and predicts favorable prognosis in epithelial ovarian cancer

Contact Info

Product

Resources

About